Adrenocortical Carcinoma Global Market Report 2025

Description

Adrenocortical carcinoma (ACC) is a rare and aggressive form of cancer that begins in the outer layer (cortex) of the adrenal glands. The adrenal glands are small, triangular organs located on top of each kidney and are responsible for producing hormones that regulate metabolism, immune function, blood pressure, and stress response. ACC can disrupt hormone production, leading to symptoms such as weight gain, high blood pressure, and virilization (the development of male physical traits).

There are two main types of adrenocortical carcinoma, localized and metastatic. Localized adrenocortical carcinoma is a rare and aggressive cancer that remains confined to the adrenal gland, without spreading to other areas of the body. Treatment for these conditions involves various methods, including surgery, chemotherapy, targeted therapy, radiation therapy, and adjuvant therapy. The primary end users of these treatments are hospitals, clinics, ambulatory surgical centers, and cancer research institutions.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The adrenocortical carcinoma market research report is one of a series of new reports from The Business Research Company that provides adrenocortical carcinoma market statistics, including the adrenocortical carcinoma industry global market size, regional shares, competitors with the adrenocortical carcinoma market share, detailed adrenocortical carcinoma market segments, market trends, and opportunities, and any further data you may need to thrive in the adrenocortical carcinoma industry. This adrenocortical carcinoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The adrenocortical carcinoma market size has grown steadily in recent years. It will grow from $3.6 billion in 2024 to $3.76 billion in 2025 at a compound annual growth rate (CAGR) of 4.4%. The growth in the historic period can be attributed to increasing incidence of adrenocortical carcinoma, growing awareness of rare endocrine tumors, increased government and research funding, growing patient support and advocacy groups, and rising prevalence of rare cancers.

The adrenocortical carcinoma market size is expected to see steady growth in the next few years. It will grow to $4.44 billion in 2029 at a compound annual growth rate (CAGR) of 4.3%. The growth in the forecast period can be attributed to increased use of combination therapies, rising adoption of personalized medicine approaches, expanding clinical trials, increased participation in international research networks, and increased government and research funding. Major trends in the forecast period include advancements in genomic sequencing and personalized medicine, targeted therapy innovations, immunotherapy developments, liquid biopsy technology, and advances in biomarker identification.

The forecast of 4.3% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff escalations are likely to burden U.S. cancer patients by driving up the cost of mitotane analogs and targeted kinase inhibitors sourced from Italy and India, exacerbating specialty pharmacy expenses and limiting precision therapy access. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The rising prevalence of rare cancers is expected to drive the growth of the adrenocortical carcinoma (ACC) market in the future. Rare cancers are characterized by their low incidence rates and their significant impact on patient outcomes, requiring specialized techniques for diagnosis and treatment. The increase in rare cancer cases can be attributed to various factors, including advancements in diagnostic methods that have improved the detection of adrenocortical carcinoma, enabling earlier identification of cases that might have previously gone undiagnosed. Adrenocortical carcinoma, a relatively uncommon yet aggressive form of cancer, contributes to the growing prevalence of rare cancers, emphasizing the need for better diagnosis and treatment approaches. For example, a report from the International Agency for Research on Cancer, part of the World Health Organization, noted in February 2022 that nearly six new cases of rare cancers are diagnosed annually per 100,000 individuals in the US. As a result, the increase in the prevalence of rare cancers is expected to fuel the expansion of the adrenocortical carcinoma market.

Key players in the adrenocortical carcinoma (ACC) market are focusing on the development of innovative therapies, such as small-molecule drugs, to target specific tumor pathways and enhance patient outcomes. Small-molecule drugs are low molecular weight compounds that enter cells to target proteins or enzymes, thereby regulating biological processes and treating diseases such as adrenocortical carcinoma by inhibiting tumor growth pathways. For example, in January 2023, Orphagen Pharmaceuticals, Inc., a pharmaceutical company based in the United States, announced that the U.S. Food and Drug Administration (FDA) had granted Rare Pediatric Disease Designation (RPDD) for its investigational drug OR-449, which is being developed to treat pediatric adrenocortical carcinoma (ACC). This drug specifically targets pediatric ACC, a rare and aggressive cancer that primarily affects children. The disease often manifests with symptoms related to hormonal overproduction, such as virilization and Cushing syndrome. Diagnosis is typically carried out through imaging and hormonal assessments, with prognosis influenced by factors such as the age of diagnosis and the resectability of the tumor.

In October 2024, Esteve Pharmaceuticals, S.A., a pharmaceutical company based in Spain, acquired HRA Pharma Rare Diseases from Perrigo Company plc for an undisclosed amount. Through this acquisition, Esteve Pharmaceuticals seeks to broaden its portfolio of treatments for rare diseases, accelerate its international expansion, improve patient care, and expand its market presence. HRA Pharma Rare Diseases, based in France, is a pharmaceutical company focused on treating rare diseases, including adrenocortical carcinoma.

Major players in the adrenocortical carcinoma market are Roche Holding AG, Merck & Co. Inc., Sanofi S.A., Bristol-Myers Squibb Company, AstraZeneca PLC, Medtronic plc, Eli Lilly and Company, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Sun Pharmaceutical Industries Ltd., Ipsen S.A., Ferring Pharmaceuticals Inc., Exelixis Inc., Alnylam Pharmaceuticals Inc., Mylan N.V., HRA Pharma S.A., Servier Laboratories, Tempest Therapeutics Inc., Orphagen Pharmaceuticals Inc., and Millendo Therapeutics Inc.

North America was the largest region in the adrenocortical carcinoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in adrenocortical carcinoma report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the adrenocortical carcinoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The adrenocortical carcinoma market consists of revenues earned by entities by providing services such as diagnostic services, medical treatments, patient management services, clinical trials, and research. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Adrenocortical Carcinoma Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on adrenocortical carcinoma market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on the latest market shares.
Benchmark performance against key competitors.
Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for adrenocortical carcinoma ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The adrenocortical carcinoma market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The market characteristics section of the report defines and explains the market.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

Markets Covered:1) By Type: Localized Adrenocortical Carcinoma; Metastatic Adrenocortical Carcinoma
2) By Therapy: Surgery; Laparoscopic Surgery; Open Surgery; Chemotherapy; Targeted Therapy; Radiation Therapy; External Beam Radiation Therapy; Bratchytherapy; Adjuvant Therapy; Other Therapy
3) By End User: Hospitals And Clinics; Ambulatory Surgical Centers; Cancer Research Institutes
Subsegments:
1) By Localized Adrenocortical Carcinoma: Early-Stage Localized Adrenocortical Carcinoma; Advanced Localized Adrenocortical Carcinoma
2) By Metastatic Adrenocortical Carcinoma: Metastasis To Distant Organs; Local Regional Metastasis
Companies Mentioned: Roche Holding AG; Merck & Co. Inc.; Sanofi S.A.; Bristol-Myers Squibb Company; AstraZeneca PLC; Medtronic plc; Eli Lilly and Company; Teva Pharmaceutical Industries Ltd.; Astellas Pharma Inc.; Sun Pharmaceutical Industries Ltd.; Ipsen S.A.; Ferring Pharmaceuticals Inc.; Exelixis Inc.; Alnylam Pharmaceuticals Inc.; Mylan N.V.; HRA Pharma S.A.; Servier Laboratories; Tempest Therapeutics Inc.; Orphagen Pharmaceuticals Inc.; Millendo Therapeutics Inc.
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.

Product Code: r33635u

1. Executive Summary

2. Adrenocortical Carcinoma Market Characteristics

3. Adrenocortical Carcinoma Market Trends And Strategies

4. Adrenocortical Carcinoma Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global Adrenocortical Carcinoma Growth Analysis And Strategic Analysis Framework

5.1. Global Adrenocortical Carcinoma PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
5.2. Analysis Of End Use Industries
5.3. Global Adrenocortical Carcinoma Market Growth Rate Analysis
5.4. Global Adrenocortical Carcinoma Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
5.5. Global Adrenocortical Carcinoma Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
5.6. Global Adrenocortical Carcinoma Total Addressable Market (TAM)

6. Adrenocortical Carcinoma Market Segmentation

6.1. Global Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Localized Adrenocortical Carcinoma
Metastatic Adrenocortical Carcinoma
6.2. Global Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Surgery
Laparoscopic Surgery
Open Surgery
Chemotherapy
Targeted Therapy
Radiation Therapy
External Beam Radiation Therapy
Brachytherapy
Adjuvant Therapy
Other Therapy
6.3. Global Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals And Clinics
Ambulatory Surgical Centers
Cancer Research Institutes
6.4. Global Adrenocortical Carcinoma Market, Sub-Segmentation Of Localized Adrenocortical Carcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Early-Stage Localized Adrenocortical Carcinoma
Advanced Localized Adrenocortical Carcinoma
6.5. Global Adrenocortical Carcinoma Market, Sub-Segmentation Of Metastatic Adrenocortical Carcinoma, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Metastasis To Distant Organs
Local Regional Metastasis

7. Adrenocortical Carcinoma Market Regional And Country Analysis

7.1. Global Adrenocortical Carcinoma Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
7.2. Global Adrenocortical Carcinoma Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Adrenocortical Carcinoma Market

8.1. Asia-Pacific Adrenocortical Carcinoma Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.2. Asia-Pacific Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.3. Asia-Pacific Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8.4. Asia-Pacific Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Adrenocortical Carcinoma Market

9.1. China Adrenocortical Carcinoma Market Overview
9.2. China Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.3. China Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
9.4. China Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Adrenocortical Carcinoma Market

10.1. India Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.2. India Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
10.3. India Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Adrenocortical Carcinoma Market

11.1. Japan Adrenocortical Carcinoma Market Overview
11.2. Japan Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.3. Japan Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11.4. Japan Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Adrenocortical Carcinoma Market

12.1. Australia Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.2. Australia Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12.3. Australia Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Adrenocortical Carcinoma Market

13.1. Indonesia Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.2. Indonesia Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13.3. Indonesia Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Adrenocortical Carcinoma Market

14.1. South Korea Adrenocortical Carcinoma Market Overview
14.2. South Korea Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.3. South Korea Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14.4. South Korea Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Adrenocortical Carcinoma Market

15.1. Western Europe Adrenocortical Carcinoma Market Overview
15.2. Western Europe Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.3. Western Europe Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15.4. Western Europe Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Adrenocortical Carcinoma Market

16.1. UK Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.2. UK Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16.3. UK Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Adrenocortical Carcinoma Market

17.1. Germany Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.2. Germany Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17.3. Germany Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Adrenocortical Carcinoma Market

18.1. France Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.2. France Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18.3. France Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Adrenocortical Carcinoma Market

19.1. Italy Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.2. Italy Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19.3. Italy Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Adrenocortical Carcinoma Market

20.1. Spain Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.2. Spain Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20.3. Spain Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Adrenocortical Carcinoma Market

21.1. Eastern Europe Adrenocortical Carcinoma Market Overview
21.2. Eastern Europe Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.3. Eastern Europe Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21.4. Eastern Europe Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Adrenocortical Carcinoma Market

22.1. Russia Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.2. Russia Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22.3. Russia Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Adrenocortical Carcinoma Market

23.1. North America Adrenocortical Carcinoma Market Overview
23.2. North America Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.3. North America Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23.4. North America Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Adrenocortical Carcinoma Market

24.1. USA Adrenocortical Carcinoma Market Overview
24.2. USA Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.3. USA Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24.4. USA Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Adrenocortical Carcinoma Market

25.1. Canada Adrenocortical Carcinoma Market Overview
25.2. Canada Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.3. Canada Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25.4. Canada Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Adrenocortical Carcinoma Market

26.1. South America Adrenocortical Carcinoma Market Overview
26.2. South America Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.3. South America Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26.4. South America Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Adrenocortical Carcinoma Market

27.1. Brazil Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.2. Brazil Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27.3. Brazil Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Adrenocortical Carcinoma Market

28.1. Middle East Adrenocortical Carcinoma Market Overview
28.2. Middle East Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.3. Middle East Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28.4. Middle East Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Adrenocortical Carcinoma Market

29.1. Africa Adrenocortical Carcinoma Market Overview
29.2. Africa Adrenocortical Carcinoma Market, Segmentation By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.3. Africa Adrenocortical Carcinoma Market, Segmentation By Therapy, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29.4. Africa Adrenocortical Carcinoma Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Adrenocortical Carcinoma Market Competitive Landscape And Company Profiles

30.1. Adrenocortical Carcinoma Market Competitive Landscape
30.2. Adrenocortical Carcinoma Market Company Profiles
- 30.2.1. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Sanofi S.A. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis

31. Adrenocortical Carcinoma Market Other Major And Innovative Companies

31.1. Medtronic plc
31.2. Eli Lilly and Company
31.3. Teva Pharmaceutical Industries Ltd.
31.4. Astellas Pharma Inc.
31.5. Sun Pharmaceutical Industries Ltd.
31.6. Ipsen S.A.
31.7. Ferring Pharmaceuticals Inc.
31.8. Exelixis Inc.
31.9. Alnylam Pharmaceuticals Inc.
31.10. Mylan N.V.
31.11. HRA Pharma S.A.
31.12. Servier Laboratories
31.13. Tempest Therapeutics Inc.
31.14. Orphagen Pharmaceuticals Inc.
31.15. Millendo Therapeutics Inc.

32. Global Adrenocortical Carcinoma Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Adrenocortical Carcinoma Market

34. Recent Developments In The Adrenocortical Carcinoma Market

35. Adrenocortical Carcinoma Market High Potential Countries, Segments and Strategies

35.1 Adrenocortical Carcinoma Market In 2029 - Countries Offering Most New Opportunities
35.2 Adrenocortical Carcinoma Market In 2029 - Segments Offering Most New Opportunities
35.3 Adrenocortical Carcinoma Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies

36. Appendix

36.1. Abbreviations
36.2. Currencies
36.3. Historic And Forecast Inflation Rates
36.4. Research Inquiries
36.5. The Business Research Company
36.6. Copyright And Disclaimer